Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
PRIMSOL (trimethoprim hydrochloride) is an oral antibiotic solution approved in 2000 for treating bacterial infections, particularly urinary tract infections. Trimethoprim works by inhibiting bacterial dihydrofolate reductase, disrupting nucleotide synthesis and preventing bacterial cell division. It is a narrow-spectrum agent commonly used for uncomplicated UTIs and as prophylaxis in specific patient populations.
As a mature product approaching loss of exclusivity, the brand team is likely focused on defensive strategies and operational efficiency rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
PRIMSOL offers limited career growth opportunities given its LOE-approaching lifecycle and minimal linked job postings. Roles available are primarily in defensive commercial activities such as market access, price negotiation, and customer retention rather than innovation or expansion.
Worked on PRIMSOL at TerSera Therapeutics? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.